e l f Beauty Inc vs Vaxcyte Inc. Common Stock — how do they compare? e l f Beauty Inc trades at $107.01 (market cap $6.38B), while Vaxcyte Inc. Common Stock trades at $67.37 (market cap $10.51B). The key difference: Vaxcyte Inc. Common Stock is the larger of the two by market cap, and Vaxcyte Inc. Common Stock is trading nearer its 52-week high, e l f Beauty Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold e l f Beauty Inc for 26 Days and Vaxcyte Inc. Common Stock for 0 Days on average.
| ELF | PCVX | |
|---|---|---|
Market Cap | $6.38B | $10.51B |
Volume | 856,198 | 2,644,694 |
Sector | Consumer Staples | Health |
52-Week High | $136.92 | $73.82 |
52-Week Low | $49.57 | $40.32 |
Typical Hold Time | 26 Days | 0 Days |
Enterprise Value | $6.97B | $9.14B |
Signals from Pluang's Aura AI — not financial advice
ELF Beauty trades at $108.16, down 1.62% today, with strong technical momentum showing bullish moving averages but overbought RSI readings. The company demonstrates robust revenue growth with Q2 2026 earnings beating expectations by 145%, though valuation metrics remain elevated with a P/E of 110.37. Recent expansion includes rhode brand launches in 19 European markets via Sephora and innovative marketing campaigns like the 'Mirror Mix' music album.
Outlook remains positive with analyst consensus leaning bullish (48% buy ratings) despite premium valuation. Key opportunities include international expansion and market share gains, while risks center on margin compression and competitive pressures in the beauty sector. The stock trades above consensus price target of $95.91, suggesting near-term consolidation potential.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
e.l.f. Beauty is a leading cosmetics company offering high-quality, 100% vegan, and cruelty-free products. It is known for its affordable and prestige-quality makeup and skincare items for a diverse global audience.
Read more on ELF →Vaxcyte, Inc. is a clinical-stage vaccine company that engineers protein-based vaccines to prevent bacterial diseases such as invasive pneumococcal disease, using its proprietary cell-free protein synthesis platform to develop candidates including the pneumococcal conjugate vaccines VAX-31 and VAX-24.
Read more on PCVX →